Structure Therapeutics Inc., a biopharmaceutical company, is set to release topline data from its clinical program of aleniglipron, a GLP-1 receptor agonist for obesity treatment, on December 8, 2025. A conference call and webcast will follow the release. Interested individuals can access the webcast on the company’s Investor Relations page or via phone. The webcast will be available for replay on the company’s website for 90 days. Structure Therapeutics focuses on developing oral small molecule treatments for metabolic conditions. For more information, visit their website. Investors can contact Danielle Keatley, while media inquiries can reach Dan Budwick.

Read more at GlobeNewswire: Structure Therapeutics to Report Data from ACCESS Clinical